drugset / Trial / NCT04623814

the Safety, Tolerability, and Pharmacokinetics Study of HEC113995

NCT04623814 ↗

Phase 1 Completed 58 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedSequentialDouble-blindTreatment

Summary

Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC113995 PA•H2O in Healthy Subjects

Timeline

Start
2020-03-30
Primary completion
2020-08-12
Completion
2020-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC113995 Unknown 10 mg Oral
Subject HEC113995 Unknown 20 mg Oral
Subject HEC113995 Unknown 40 mg Oral